

## Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Ross AL, Bråve A, Scarlatti G, Manrique A, Buonaguro L. Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. *Lancet Infect Dis* 2010; **10**: 305–316.

**Table I S.** List of ongoing HIV-1 vaccine clinical trials in the different Phases of experimentation.

Phase	Trial ID	Start Date	Strategy	Candidate	Volunteers	Trial Sites	Clade
<b>II</b>							
<b>Ila</b>	HVTN 205	12/1/2009	DNA/Viral Vector – Pox	pGA2/JS7 DNA/MVA/HIV62	225	U.S., Peru	B
<b>II</b>	HVTN 505	6/7/2009	DNA/Viral Vector – Adeno	VRC-HIVDNA016-00-VP/VRC-HIVADV014-00-VP	1350	U.S.	multiclade
<b>II</b>	TaMoVac 01	6/01/2010	DNA/ Viral vector - Pox (MVA)	HIVIS DNA/MVA-CMDR	120	Tanzania	multiclade
<b>I</b>							
<b>Ib</b>	HVTN 077	1/1/2009	Viral Vector - Adeno/Viral Vector - Adeno/DNA	VRC-HIVADV027-00-VP/VRC-HIVADV038-00-VP/VRC-HIVDNA044-00-VP	192	U.S.	B
<b>I/II</b>	HIVIS 03	01/12/2006	DNA/Viral Vector – Pox	HIVIS-DNA/MVA-CMDR	60	Tanzania	multiclade
<b>I/II</b>	NCHECR-AE1	1/7/2007	DNA/Viral Vector – Pox	pHIS-HIV-AE/rFPV-HIV-AE	8	Thailand	AE
<b>I</b>	Ad26.ENVA.01	2/1/2008	Viral Vector – Adeno	Ad26.EnVA-01	48	USA	A
<b>I</b>	Ad5HVR48.ENVA.01	2/2/2009	Viral Vector – Adeno	Ad5HVR48.ENVA.01	48	USA	A
<b>I</b>	HIVIS 05	18/03/2009	DNA/Viral Vector – Pox	HIVIS-DNA/MVA-CMDR	24	Sweden	multiclade
<b>I</b>	HPTN 027	01/10/2006	Viral Vector – Pox	ALVAC-HIV vCP1521	50	Uganda	E/B
<b>I</b>	HPTN 027	01/10/2006	Viral Vector – Pox	ALVAC-HIV vCP1521	50	Uganda	E/B
<b>I</b>	HVRF-380-131004	01/03/2006	Protein	Vichrepol	15	Russia	B
<b>I</b>	HVTN 070	23/10/2007	DNA	PENNVAX-B	120	USA	B
<b>I</b>	HVTN 073	1/6/2009	DNA/Viral Vector – Pox	SAAVI DNA-C2/SAAVI MVA-C	48	U.S., SA	C
<b>I</b>	IAVI B001	2/28/2009	Viral Vector - Adeno/Viral Vector – Adeno	Ad35-GRIN/ENV/Ad35-GRIN/ENV	42	U.S.	A
<b>I</b>	IAVI P001	2/4/2009	DNA/Viral Vector – Pox	ADVAX/TBC-M4	32	India	C
<b>I</b>	IAVI P002	1/11/2008	DNA/Viral Vector – Pox	ADVAX/TBC-M4	32	England	B
<b>I</b>	RV 138; B011	1/3/2006	Viral Vector – Pox	ALVAC-HIV MN120TMG strain (vCP205)	36	U.S.	B
<b>I</b>	RV 156A	4/30/2007	DNA/Viral Vector – Adeno	VRC-HIVDNA009-00-VP/VRC-HIVADV014-00-VP	29	Uganda	multiclade
<b>I</b>	RV 158	1/7/2005	Viral Vector – Pox	MVA-CMDR	48	U.S., Thailand	AE
<b>I</b>	Tiantian vaccinia HIV Vaccine	9/3/2009	DNA/Viral Vector – Pox	Chinese DNA /Tiantian vaccinia	80	China	C
<b>I</b>	VRC 011(06-I-0149)	6/4/2006	DNA/Viral Vector – Adeno	VRC-HIVDNA016-00-VP/VRC-HIVADV014-00-VP	60	U.S.	multiclade
<b>I</b>	VRC 012 (07-I-0167)	1/5/2007	Viral Vector - Adeno/Viral Vector – Adeno	VRC-HIVADV027-00-VP/VRC-HIVADV038-00-VP	35	U.S.	A
<b>I</b>	VRC 015 (08-I-0171)	1/6/2008	Viral Vector – Adeno	VRC-HIVADV014-00-VP	40	U.S.	multiclade
<b>I</b>	HIVIS 07	5/01/2010	DNA/ Viral vector - Pox (MVA)	HIVIS DNA/MVA-CMDR	40	Sweden	multiclade

**Table II S.** List of withdrawn, suspended or terminated HIV-1 vaccine clinical trials in the different Phases of experimentation.

Phase	Trial ID	Start Date	Strategy	Candidate	Volunteers	Trial Sites	Clade	Status
-------	----------	------------	----------	-----------	------------	-------------	-------	--------



II	IAVI A002	1/11/2005	Viral Vector - Adeno-associated Virus	tgAAC09	84	ZA, UG, ZM	C
I							
Ib	HVTN_052	01/12/2003	DNA	VRC-HIVDNA09-00-VP	180	USA	multiclade A, B, C
Ib	HVTN_069	29/11/2006	DNA/Viral Vector - Adeno VRC-HIVDNA09-00-VP/VRC-HIVADV014-00-VP	90		USA	
I/II	EV03/ANRSVAC20	07/01/2007	DNA/Viral Vector - Pox	DNA-C/MNVAC-C	147	UK, DE, CH, F	C
I/II	ACTG 326; PACTG 326	12/15/1997	Viral Vector - Pox/Protein in children	ALVAC vCP1452/AIDSVAX B/B	48	USA	B
I/II	C060301	1/2/2004	DNA	GTU-MultiHIV	28	FI	B
I/II	EV02 (EuroVacc 02)	1/6/2007	DNA/Viral Vector - Pox	DNA-C/MNVAC-C		UK, CH	C
I/II	F4/AS01		Protein	F4/AS01		Europe	
I/II	HVTN 042 / ANRS VAC 19	01/05/2004	Viral Vector - Pox/Protein	ALVAC vCP1452/LIPO-5	174	USA	B
I/II	IAVI 006	4/4/2002	DNA/Viral Vector - Pox	DNA.HIVA /MVA.HIVA	120	UK	A
I/II	RV 132	1/3/2000	Viral Vector - Pox/Protein/Protein	ALVAC-HIV vCP1521/gp160 THO23/LAI-DID/rfp120/HIV-1 SF-2	120	TH	B
I/II	RV 135	1/4/2000	Viral Vector - Pox/Protein	ALVAC-HIV vCP1521/gp120 C4-V3	120	TH	E
I/II	RV 172	1/5/2005	DNA/Viral Vector - Adeno	VRC-HIVDNA016-00-VP/VRC-HIVADV014-00-VP	326	KE, UG, TZ	multiclade
I/II	UBI HIV-1MN octameric - Australia study	1/11/1993	Protein	UBI HIV-1 Peptide Immunogen, Multivalent 24	24	AU	B
I/II	UBI V106	1/11/1999	Protein	UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent	24	USA	B
I/II	VAX 002	11/2/1999	Protein/Protein	AIDSVAX B/B/AIDSVAX B/E	120	USA	B/E
I	01-I-0079	1/30/2001	DNA	VRC430221	21	USA	B
I	04/400-003-04	11/2/1999	DNA	APL 400-003 GENEVAX-HIV	18	USA	B
I	87 I-114	8/1987	Protein	gp160	138	USA	B
I	96-I-0050	3/16/1996	DNA	APL 400-003 GENEVAX-HIV	32	USA	B
I	ANRS VAC 01	6/1/1992	Viral Vector - Pox/Protein	ALVAC vCP125/gp160 Vaccine (Immuno-AG)	20	FR	B
I	ANRS VAC 02	7/1/1992	Protein rgp 160 + peptide V3	ANRS VAC 02	25	FR	B
I	ANRS VAC 03	3/1/1994	Viral Vector - Pox/Protein	ALVAC-HIV MN120TMG strain (vCP205)/CLTB-36 (gp24E-V3 MN)	30	FR	B
I	ANRS VAC 04	11/21/1996	Protein (Lipopeptides)	LIPO-6	28	FR	B
I	ANRS VAC 04 bis	12/1/1998	Protein (Lipopeptides)	LIPO-6	23	FR	B
I	ANRS VAC 05	4/1/1995	Viral Vector - Pox/Viral Vector - Pox	ALVAC vCP125/ALVAC (VCP rage)	15	FR	B
I	ANRS VAC 06	5/1/1995	Viral Vector - Pox/Viral Vector - Pox	ALVAC vCP125/ALVAC (VCP rage)	16	FR	B
I	ANRS VAC 07	4/1/1995	Viral Vector - Pox	ALVAC vCP300	20	FR	B
I	ANRS VAC 08	12/1/1999	Viral Vector - Pox	ALVAC-HIV MN120TMG strain (vCP205)	13	FR	B
I	ANRS VAC 10	3/1/1999	Viral Vector - Pox/Protein (Lipopeptides)	ALVAC vCP1452/LIPO-6T/LIPO-5	60	FR	B
I	ANRS VAC 12	5/1/2001	Protein (Lipopeptides)	LPHIV1	15	FR	B
I	ANRS VAC 17		Protein (Lipopeptides)	LIPO-6	35	FR	B
I	AVEG 002	11/29/1988	Viral Vector - Pox (Vaccinia) /Protein	HIVAC-1e/gp160 MN/LAI	54	USA	B
I	AVEG 002A	5/6/1991	Viral Vector (Vaccinia) - Pox	HIVAC-1e	35	USA	B
I	AVEG 002B	3/28/1991	Viral Vector (Vaccinia)- Pox/Protein	HIVAC-1e/VaxSyn gp160 Vaccine (MicroGeneSys)	13	USA	B
I	AVEG 003	5/5/1988	Protein	VaxSyn gp160 Vaccine (MicroGeneSys)	72	USA	B
I	AVEG 003A	10/30/1990	Protein	VaxSyn gp160 Vaccine (MicroGeneSys)	30	USA	B
I	AVEG 003B	12/13/1990	Protein	VaxSyn gp160 Vaccine (MicroGeneSys)	25	USA	B
I	AVEG 004	12/13/1990	Protein	gp160 Vaccine (Immuno-AG)	60	USA	B
I	AVEG 004A	8/4/1992	Protein	gp160 Vaccine (Immuno-AG)	25	USA	B

I	AVEG 004B	12/11/1991	Protein	gp160 Vaccine (Immuno-AG)	30	USA	B
I	AVEG 005A/B	1/28/1991	Protein	Env 2-3 (gp120)	64	USA	B
I	AVEG 005C	10/30/1991	Protein	Env 2-3 (gp120)	14	USA	B
I	AVEG 006X; VEU 006	3/25/1991	Protein	MN rgp120	28	USA	B
I	AVEG 007A/B	12/31/1991	Protein	rgp120/HIV-1 SF-2	49	USA	B
I	AVEG 007C	11/16/1992	Protein	rgp120/HIV-1 SF-2	14	USA	B
I	AVEG 008	7/3/1992	Viral Vector – Pox (Vaccinia) and Protein/Protein	HIVAC-1e/ Env 2-3 (gp120) and gp160 (Immuno-AG)	56	USA	B
I	AVEG 009	3/20/1992	Protein	MN rgp120	57	USA	B
I	AVEG 010	7/16/1992	Viral Vector - Pox (Vaccinia) /Protein/Protein	HIVAC-1e/rgp120/HIV-1 SF-2/MN rgp120	56	USA	B
I	AVEG 011	4/2/1993	Protein	UBI HIV-1 Peptide Immunogen, Multivalent	40	USA	B
I	AVEG 012A/B	19/5/93	Viral Vector – Pox	ALVAC vCP125	28	USA	B
I	AVEG 013A	4/4/1993	Protein	gp160 Vaccine (Immuno-AG)	24	USA	B
I	AVEG 013B	23/1/95	Protein	gp160 Vaccine (Immuno-AG)	20	USA	B
I	AVEG 014A/B	13/4/94	Viral Vector – Pox	TBC-3B	18	USA	B
I	AVEG 014C	7/6/1993	Viral Vector - Pox/Protein	TBC-3B/MN rgp120	36	USA	B
I	AVEG 015	7/6/1993	Protein	rgp120/HIV-1 SF-2	112	USA	B
I	AVEG 016	16/6/93	Protein	MN rgp120	81	USA	B
I	AVEG 016A	17/5/94	Protein	MN rgp120	118	USA	B
I	AVEG 016B	20/11/96	Protein	MN rgp120	37	USA	B
I	AVEG 017	14/2/94	Protein	UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent	28	USA	A, B, C, D, E
I	AVEG 018	27/6/94	Protein	UBI HIV-1 Peptide Vaccine, Microparticulate Monovalent	32	USA	B
I	AVEG 019	4/5/1995	Virus Like Particles	p17/p24:Ty- VLP	36	USA	B
I	AVEG 020	22/10/97	Protein	gp120 C4-V3	24	USA	B
I	AVEG 021	4/1/1995	Protein	P3C541b Lipopeptide	30	USA	B
I	AVEG 022	1/5/1995	Viral Vector – Pox	ALVAC-HIV MN120TMG strain (vCP205)	76	USA	B
I	AVEG 022A	10/6/1996	Viral Vector - Pox/Protein	ALVAC-HIV MN120TMG strain (vCP205)/rgp120/HIV-1 SF-2	150	USA	B
I	AVEG 023	18/5/95	Protein	UBI HIV-1 Peptide Immunogen, Multivalent	36	USA	B / A, B, C, D, E
I	AVEG 024	18/9/95	Protein	rgp120/HIV-1 SF-2	30	USA	B
I	AVEG 026	6/2/1996	Viral Vector - Pox/Protein	ALVAC vCP300/rgp120/HIV-1 SF-2	140	USA	B
I	AVEG 027	3/11/1999	Viral Vector – Pox	ALVAC-HIV MN120TMG strain (vCP205)	84	USA	B
I	AVEG 028	5/12/1997	Bacterium + gp 120/Protein Salmonella typhi	CVD 908- HIV-1 LAI gp 120 /MN rgp120	47	USA	B
I	AVEG 029	31/7/96	Viral Vector - Pox/Protein	ALVAC-HIV MN120TMG strain (vCP205)/rgp120/HIV-1 SF-2	35	USA	B
I	AVEG 031	16/7/97	DNA/Viral Vector – Pox	APL 400-047/ALVAC-HIV MN120TMG strain (vCP205)	40	USA	B
I	AVEG 032	5/8/1999	Viral Vector - Pox/Protein	ALVAC-HIV MN120TMG strain (vCP205)/rgp120/HIV-1 SF-2	64	USA	B
I	AVEG 033	21/1/98	Viral Vector – Pox	ALVAC-HIV MN120TMG strain (vCP205)	36	USA	B
I	AVEG 034/034A	17/6/98	Viral Vector - Pox/Viral Vector - Pox/Viral Vector – Pox	ALVAC vCP1433/ALVAC vCP1452/ALVAC-HIV MN120TMG strain (vCP205)	100	USA	B
I	AVEG 036	12/3/1998	Protein/Protein	MN rgp120/AIDS VAX B/E	60	USA	B/E
I	AVEG 038	13/3/2000	Viral Vector – Pox	ALVAC-HIV MN120TMG strain (vCP205)	60	USA	B

I	C86P1	1/9/2006	Protein	HIV gp140 ZM96	30	UK	C
I	DP6-001	1/4/2004	DNA/Protein	DP6-001 DNA /DP6 protein	36	USA	A,B,C,E
I	EnvPro	1/6/2003	Protein	EnvPro	10	USA	D
I	EV01	1/7/2003	Viral Vector – Pox	NYVAC-C	24	UK, CH	C
I	FIT Biotech	01/07/2002	DNA	GTU-Nef	14	FI	
I	Guangxi CDC DNA vaccine	01/03/2005	DNA	Chinese DNA	49	CN	multicladde
I	HGP-30 memory responses		Protein	HGP-30	11		
I	HIVIS 01	01/02/2006	DNA	HIVIS-DNA	40	SE	multicladde
I	HIVIS 02	01/01/2006	Viral Vector – Pox	MVA-CMDR	38	SE	
I	HIVNET 007	08/02/1999	Viral Vector – Pox	ALVAC-HIV MN120TMG strain (vCP205)	40	UG	B
I	HIVNET 007	08/02/1999	Viral Vector – Pox	ALVAC-HIV MN120TMG strain (vCP205)	40	UG	B
I	HIV-POL-001	01/10/2006	Viral Vector – Pox	MVA-mBN32	36	DE	
I	HVTN 039	03/12/2003	Viral Vector – Pox	ALVAC vCP1452	110	USA	B
I	HVTN 040	01/07/2003	Viral Vector - Alphavirus	AVX101	132	USA, ZA	C
I	HVTN 041	01/02/2002	Protein	rgp120w61d	84	USA	
I	HVTN 044	01/12/2003	DNA	VRC-HIVDNA009-00-VP	70	USA	multicladde
I	HVTN 045	23/01/2003	DNA	pGA2/157 DNA	30	USA	B
I	HVTN 048	01/04/2003	DNA	EP HIV-1090	42	USA, BW	B
I	HVTN 049	01/12/2003	DNA/Protein	Gag and Env DNA/PLG microparticles/Oligomeric gp140/MF59	96	USA	B
I	HVTN 054	01/04/2005	Viral Vector – Adeno	VRC-HIVADV014-00-VP	48	USA	multicladde
I	HVTN 055	01/07/2004	Viral Vector - Pox/Viral Vector - Pox/Viral Vector – Pox	TBC-M335/TBC-M358/TBC-F357	150	USA, BR	B
I	HVTN 056	01/04/2004	Protein	MEP	96	USA	B
I	HVTN 057	18/11/2004	DNA/Viral Vector – Adeno	VRC-HIVDNA009-00-VP/VRC-HIVADV014-00-VP	70	USA	multicladde
I	HVTN 059	01/10/2004	Viral Vector - Alphavirus	AVX101	96	USA, ZA, BW	C
I	HVTN 060	01/08/2005	DNA	HIV-1 gag DNA	144	USA, TH	B
I	HVTN 063	08/09/2005	DNA	HIV-1 gag DNA	156	USA	B
I	IAVI 001	1/8/2000	DNA	DNA.HIVA	18	UK	A
I	IAVI 002	1/2/2001	DNA	DNA.HIVA	18	KE	A
I	IAVI 003	3/14/2001	Viral Vector – Pox	MVA.HIVA	8	UK	A
I	IAVI 004	6/2/2002	Viral Vector – Pox	MVA.HIVA	18	KE	A
I	IAVI 005	1/10/2001	DNA/Viral Vector – Pox	DNA.HIVA /MVA.HIVA	8	UK	A
I	IAVI 008	1/1/2003	Viral Vector – Pox	MVA.HIVA	8	KE	A
I	IAVI 009	1/13/2003	DNA/Viral Vector – Pox	DNA.HIVA /MVA.HIVA	50	UG	A
I	IAVI 011	1/11/2003	Viral Vector – Pox	MVA.HIVA	111	ZA, UK, CH	A
I	IAVI 016	1/2/2004	Viral Vector - Pox/DNA/Viral Vector – Pox	MVA.HIVA/DNA.HIVA /MVA.HIVA 24		KE, USA	A
I	IAVI A001	1/12/2003	Viral Vector - Adeno-associated Virus	tgAAC09	80	BE, DE, IN	C
I	IAVI C001	1/12/2003	DNA	ADVAX	45	USA	C
I	IAVI C002	1/1/2005	Viral Vector – Pox	ADMVA	48	USA	C
I	IAVI C003	1/11/2006	Viral Vector – Pox	ADMVA	8	USA	C
I	IAVI D001	1/12/2005	Viral Vector – Pox	TBC-M4	32	IN	C
I	IAVI V001	1/11/2005	DNA/Viral Vector – Adeno	VRC-HIVDNA016-00-VP/VRC-HIVADV014-00-VP	114	RW, KE	multicladde
I	ISS P-001	1/9/2003	Protein	Tat vaccine	32	IT	B
I	LFn-p24 vaccine	1/7/2004	Protein	LFn-p24	18	USA	B
I	MRC V001	11/13/1995	Protein	rgp120w61d	30	UK	
I	MRK Ad5	06/01/2004	Viral Vector – Adeno	Ad-5 HIV-1 gag (Merck)	48	USA	B

I	MRKAd5 + ALVAC	1/9/2003	Viral Vector - Adeno/Viral Vector – Pox	MRK Ad5/ALVAC-HIV MN120TMG strain (vCP205)	USA	B
I	PACTG 230		Protein/Protein	AIDS VAX B/E/rgp120/HIV-1 SF-2	USA	B
I	RV 124	4/16/1998	Viral Vector - Pox/Protein	ALVAC-HIV MN120TMG strain (vCP205)/gp160MN/LAI-2 0	USA	B
I	RV 151 / WRAIR 984	1/6/2004	Protein	LFn-p24	USA	B
I	RV 156	10/1/2005	DNA	VRC-HIVDNA009-00-VP	UG	multicladre
I	SG06RS02	1/9/2007	Protein	HIV gp140 ZM96	UK	C
I	TAB9	1/12/1996	Protein	TAB9	CU	B
I	UBI HIV-1 MN China	1/1/1993	Protein	UBI HIV-1 Peptide Immunogen, Multivalent	CN	B
I	UCLA MIG-001	1/18/2002	Viral Vector – Pox	TBC-3B	USA	B
I	UCLA MIG-003	10/28/2003	Viral Vector – Pox	ALVAC-HIV MN120TMG strain (vCP205)	USA	B
I	V24P1	2/11/1999	Protein	HIV p24/MF59 Vaccine	USA	B
I	V526-001 MRKAd5 and MRKAd6 HIV-1 Trigene Vaccines	1/5/2005	Viral Vector - Adeno/Viral Vector - Adeno/Viral Vector - Adeno MRKAd5 HIV-1 gag/pol/nef/MRKAd6 /MRKAd5+6 HIV-1	146	USA	multicladre
I	VRC 004 (03-I-0022)	11/13/2002	DNA	VRC-HIVDNA009-00-VP	USA	multicladre
I	VRC 006 (04-I-0172)	7/19/2004	Viral Vector – Adeno	VRC-HIVADV014-00-VP	USA	multicladre
I	VRC 007 (04-I-0254)	1/8/2004	DNA	VRC-HIVDNA016-00-VP	USA	multicladre
I	VRC 008 (05-I-0148)	1/5/2005	DNA/Viral Vector – Adeno	VRC-HIVDNA016-00-VP/VRC-HIVADV014-00-VP	USA	multicladre
I	VRC 009 (05-I-0081)	1/1/2005	DNA/Viral Vector – Adeno	VRC-HIVDNA009-00-VP/VRC-HIVADV014-00-VP	USA	multicladre
I	VRC 010 (05-I-0140)	4/13/2005	Viral Vector – Pox	VRC-HIVADV014-00-VP	USA	multicladre
I	DVP-1	4/5/2007	DNA/Protein/Viral Vector – Pox	EnvDNA/EnvPro/PolyEnv1	USA	A, B, C, D, E
I	EnvDNA	10/5/2005	DNA	EnvDNA	USA	A, B, C, D, E
I	HVTN 064	13/01/2006	Protein/Protein	EP HIV-1043 /EP HIV-1090	USA	B
I	HVTN 065	18/04/2006	DNA/Viral Vector – Pox	pGA2/J57 DNA/MVA/HIV62	USA	B
I	HVTN 067	26/04/2007	DNA/Viral Vector – Pox	EP-1233/MVA-mBN32	USA	C
I	IAVI C004/DHO-614	10/18/2007	DNA	ADVAX	USA	C
I	PolyEnv1	1/10/1997	Viral Vector – Pox	PolyEnv1	USA	B